Back to Search
Start Over
Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an Observational Study of Treatment Patterns and Lipid Control
- Source :
- Acta Clinica Croatica, Acta clinica Croatica, Volume 59., Issue 4., Volume 59, Issue 4, Acta Clinica Croatica, Vol 59., Iss 4., Pp 641-648 (2020)
- Publication Year :
- 2020
- Publisher :
- Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice), 2020.
-
Abstract
- Our observational study evaluated current management of elevated low-density lipoprotein cholesterol (LDL -C) in adult secondary prevention patients (all very high risk (VHR) by European guidelines) attending specialist clinics across Croatia. Data were collected retrospectively from patient records for the preceding 12 months. The subset judged to be at extreme risk (ER ; American Association of Clinical Endocrinologists (AACE) criteria; n=48) were compared with the remaining patients (VHR group; n=41). All patients were receiving statins (75.6% VHR/81.3% ER at high-intensity), with only a minority receiving concomitant lipid-lowering treatment (7.3% VHR/16.7% ER ). Median (Q1, Q3) LDL -C levels at the last visit were 1.9 (1.6, 2.4) mmol/L for VHR and 2.1 (1.5, 3.1) mmol/L for ER , with only 41.5% (95% CI 26.3-57.9) of VHR patients and 27.1% (15.3-41.9) of ER patients attaining their LDL -C targets (<br />Ova opservacijska studija analizirala je trenutno liječenje povišenih vrijednosti LDL kolesterola (LDL-C) u bolesnika koji su liječeni zbog hiperlipidemije u okviru sekundarne prevencije (prema europskim smjernicama svi su pripadali u skupinu bolesnika s vrlo visokim rizikom) i kontrolirali su se kod specijalista diljem Hrvatske. Podaci su prikupljeni retrospektivno tijekom 12 mjeseci iz bolesničke medicinske dokumentacije. Skupina bolesnika za koju je procijenjeno da je u ekstremno visokom riziku (ER ; AACE kriteriji; n=48) uspoređivana je sa skupinom s visokim rizikom (VHR skupina; n=41). Svi bolesnici su primali statine (75,6% bolesnika s VHR/81,3% bolesnika s ER liječeno je visokim dozama statina), dok je manjina bolesnika istodobno primala i drugu terapiju za snižavanje lipida (7,3% VHR/ER 16,7%). Kod posljednjeg posjeta medijan vrijednosti LDL -C (Q1, Q3) u skupini VHR iznosio je 1,9 (1,6, 2,4) mmol/L, dok je u skupini ER iznosio 2,1 (1,5, 3,1) mmol/L. Samo 41,5% (95% CI 26,3-57,9) bolesnika s VHR i 27,1% (15,3-41,9) bolesnika s ER imali su razine LDL -C unutar ciljne razine (
- Subjects :
- Adult
medicine.medical_specialty
Croatia
lcsh:Medicine
Hyperlipidemias
Internal medicine
Hyperlipidemia
Humans
Medicine
Lipid control
Original Scientific Papers
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine
Retrospective Studies
Secondary prevention
High-risk patients
Very high-risk patients
Extreme risk patients
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina
Hiperlipidemija
Sekundarna prevencija
Bolesnici s visokim rizikom
Bolesnici s vrlo visokim rizikom
Bolesnici s ekstremno visokim rizikom
business.industry
lcsh:R
General Medicine
Statin treatment
medicine.disease
Lipids
Concomitant
Observational study
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Very high risk
Extreme risk
Subjects
Details
- ISSN :
- 03539466 and 13339451
- Database :
- OpenAIRE
- Journal :
- Acta Clinica Croatica
- Accession number :
- edsair.doi.dedup.....dff0ab047654d575395b9c2fcdb36752